BioCentury
ARTICLE | Financial News

Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona follows an indirect investment in Azeria with a direct one

November 22, 2019 1:16 AM UTC
Updated on Nov 22, 2019 at 2:33 PM UTC

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into the clinic.

The U.K. investment firm expects to hold a 61% stake in Azeria Therapeutics Ltd. when the tranched round is fully invested, by virtue of its £29.5 million commitment. The balance will come from the Cancer Research Technology (CRT) Pioneer Fund, which also supplied the company's £5.5 million series A round. Sixth Element Capital manages that fund; Syncona is the fund's largest investor (see "Going Big in Britain")...

BCIQ Target Profiles

Forkhead box A1 (FOXA1)